Home Cart Sign in  
Chemical Structure| 1333377-65-3 Chemical Structure| 1333377-65-3

Structure of CHR-6494
CAS No.: 1333377-65-3

Chemical Structure| 1333377-65-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CHR-6494 is a potent and selective Haspin (Haploid Germ Cell-Specific Nuclear Protein Kinase) inhibitor that blocks H3T3ph phosphorylation.

Synonyms: CHR-6494

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CHR-6494

CAS No. :1333377-65-3
Formula : C16H16N6
M.W : 292.34
SMILES Code : CCCNC1=NN2C(C=C1)=NC=C2C3=CC4=C(NN=C4)C=C3
Synonyms :
CHR-6494
MDL No. :MFCD22666352
InChI Key :CZZCAOGIEGXMBZ-UHFFFAOYSA-N
Pubchem ID :70679308

Safety of CHR-6494

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313

Isoform Comparison

Biological Activity

Description
CHR-6494 is a potent inhibitor of haspin, with an IC50 of 2 nM. CHR-6494 inhibits histone H3T3 phosphorylation. CHR-6494 can be used in the research of cancer[1].

In Vitro:

Cell Line
Concentration Treated Time Description References
MDA-MB-435 611 nM 72 h CHR-6494 alone inhibits cell viability and induces apoptosis J Cancer. 2017 Aug 25;8(15):2933-2943
MeWo 396 nM 72 h CHR-6494 alone inhibits cell viability and induces apoptosis J Cancer. 2017 Aug 25;8(15):2933-2943
RPMI-7951 628 nM 72 h CHR-6494 alone inhibits cell viability and induces apoptosis J Cancer. 2017 Aug 25;8(15):2933-2943
COLO-792 497 nM 72 h CHR-6494 alone inhibits cell viability and induces apoptosis J Cancer. 2017 Aug 25;8(15):2933-2943
U2OS cells 600 nM 28 h To investigate the effect of CHR-6494 on the cell cycle of U2OS cells, results showed that CHR-6494 dose-dependently delayed the entry of cells into mitosis. J Cell Physiol. 2020 May;235(5):4508-4519
HeLa cells 300 nM 15 h To investigate the effect of CHR-6494 on the cell cycle of HeLa cells, results showed that CHR-6494 delayed the entry of cells into mitosis. J Cell Physiol. 2020 May;235(5):4508-4519
HK-2 cells 6.56 ± 0.02 µM 48 h Evaluate the inhibitory effect of CHR-6494 on HK-2 cell proliferation Pharmaceuticals (Basel). 2024 Oct 23;17(11):1420
NRK-49F cells 3.07 ± 0.32 µM 48 h Evaluate the inhibitory effect of CHR-6494 on NRK-49F cell proliferation Pharmaceuticals (Basel). 2024 Oct 23;17(11):1420
MDA-MB-231 cells 500 nM 48 h CHR-6494 inhibits H3T3 phosphorylation, leading to G2/M cell cycle arrest and apoptosis Oncogene. 2012 Mar 15;31(11):1408-18
HCT-116 cells 500 nM 48 h CHR-6494 inhibits H3T3 phosphorylation, leading to G2/M cell cycle arrest and apoptosis Oncogene. 2012 Mar 15;31(11):1408-18
HeLa cells 500 nM 48 h CHR-6494 inhibits H3T3 phosphorylation, leading to G2/M cell cycle arrest and apoptosis Oncogene. 2012 Mar 15;31(11):1408-18
SKBR3 200 nmol/L 72 h To evaluate the synergistic therapeutic effects of CHR-6494 with MLN8237, results showed that CHR-6494 significantly enhanced the killing effects of MLN8237 on breast cancer cells. Cancer Commun (Lond). 2021 Feb;41(2):121-139
MDA-MB-231 200 nmol/L 72 h To evaluate the synergistic therapeutic effects of CHR-6494 with MLN8237, results showed that CHR-6494 significantly enhanced the killing effects of MLN8237 on breast cancer cells. Cancer Commun (Lond). 2021 Feb;41(2):121-139

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice HCT-116 human colorectal cancer xenograft model Intraperitoneal injection 50 mg/kg Once daily for 5 consecutive days, total 15 days CHR-6494 significantly inhibits tumor growth without toxicity Oncogene. 2012 Mar 15;31(11):1408-18
Nude mice MDA-MB-231 xenograft model Oral and intraperitoneal injection 20 mg/kg 15 consecutive days To evaluate the synergistic antitumor effects of CHR-6494 with MLN8237 in vivo, results showed that the combination treatment significantly inhibited tumor growth. Cancer Commun (Lond). 2021 Feb;41(2):121-139

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.42mL

0.68mL

0.34mL

17.10mL

3.42mL

1.71mL

34.21mL

6.84mL

3.42mL

References

 

Historical Records

Categories